The Office Building of the International Biopharmaceutical Company Astrazeneca.
Cfoto | Future publication | Getty images
Astrazeneca On Monday, he said he plans to invest $ 50 billion in reinforcing his manufacturing and research capabilities of the United States by 2030, becoming the last pharmaceutical company to increase its expenses in the United States following the commercial rates of the United States.
The Anglo-suecia biotechnology company, based in Cambridge, England, said the “cornerstone” of the commitment would be a new multimillion-dollar installation to produce its control and metabolic portfolio, including its oral LPG-1 obesity pill.
The installation, planned for the Commonwealth of Virginia, will develop the largest unique manufacturing investment in Astrazeneca in the world and “will take advantage of AI, automation and data analysis to optimize production,” the company said.
The last financing will also expand research and development and manufacture of cell therapy in Maryland, Massachusetts, California, Indiana and Texas, and will create “tens of thousands of jobs,” added Astrazeneca.
The CEO Pascal Soriot said that the commitment supports the “belief in the innovation of the United States in biopharmaceuticals” and that it would support its ambition to reach the annual income of $ 80 billion by 2030, half of which is expected to come from the United States.
Astrazeneca, which was starting internationally through the development of one of the COVID-19 key vaccines, has long been prioritizing the US market. The United States represented more than 40% of the company’s annual income in 2024.
In November, shortly after the presidential elections of the United States, Astrazeneca announced an American investment of $ 3.5 billion. Earlier this month, the Times reported that the company can transfer its London list to the United States, in which analysts said it would be a great blow to the public markets of the United Kingdom.
Astrazeneca is the most valuable business that appears in the FTSE 100 in London. The company declined to comment on the Times report.
Pharmaceutical companies increase US spending.
The Astrazeneca financing announcement follows similar movements of global pharmaceutical firms, including Novartis, Sanofi and Roche and Eli Lilly and Johnson & Johnson, based in the United States, who have promised in recent months to increase their US investment that the president of the United States, Donald Trump, the demands of the domestic manufacturing of res.
The industry expects greater clarity about the pharmaceutical tariffs of the Trump administration, with the final result of an investigation of section 232 on the sector owed at the end of this month. An effort to rebalance the prices of American medicines with those paid by other countries is also underway.
Trump at the beginning of this month suggested that the industry could face taxes of up to 200%, with a brief period of grace of 12-18 months to allow companies to relocate in the United States. However, many companies and analysts have called the time frame as insufficient.
“Usually, for most medications it is a horizon of three to four years. We are working very hard to accelerate that as fast as we can and show that we are making the investments we have planned,” said the CEO of Novartis, you are going Narasimhan, last week during a gain call, and added that he hoped that the administration takes into account.
